Navigation Links
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
Date:5/28/2009

ese Encephalitis is the Company's first product on the market.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, and Sanofi Pasteur.

The Company's pipeline includes a Travelers' Diarrhea Vaccine Patch (Phase II concluded), a Pseudomonas vaccine candidate (Phase II), a Vaccine Enhancement Patch to prevent Pandemic Influenza in combination with an injected vaccine, a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, three other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit: www.intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


'/>"/>
SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
2. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
3. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
4. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
5. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
6. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
7. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
9. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
10. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
11. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... July 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... developments for the quarter ended June 30, 2014. ... 30, 2014 Revenue Total revenue for the quarter ended ... for the quarter ended June 30, 2013 primarily due to ... Total revenue for the six months ended ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... PHILADELPHIA, Jan. 5, 2011 ERT (Nasdaq: ... of technology and services to the pharmaceutical, biotechnology and ... Suicide Severity Rating Scale) solution facilitates compliance with the ... entitled "Suicidality: Prospective Assessment of Occurrence in Clinical Trials." ...
... Jan. 5, 2011 Cell Biosciences, Inc., a ... science researchers, today announced the launch of the ... imaging products, the FluorChem® M MultiFluor system. This ... fluorescent Western blots with key ease-of-use features aimed ...
Cached Medicine Technology:eC-SSRS Solution from ERT Facilitates Compliance with New FDA Guidance on Suicidality Assessment in Clinical Trials 2eC-SSRS Solution from ERT Facilitates Compliance with New FDA Guidance on Suicidality Assessment in Clinical Trials 3Cell Biosciences Launches New Platform for Multiplex Western Blot Detection 2
(Date:8/1/2014)... The "Antimicrobial Coatings Market by Type (Silver, ... Dioxide, and Zinc Omadine), Application (Indoor air/HVAC, Medical, ... Textiles, and others), & Geography (North America, Europe, ... to 2018" analyzes the Antimicrobial Coatings Market with ... the diverse geographical regions. , Browse 49 market ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Although many parents worry about ... a common choking hazard: food. Such was the ... cough after eating a handful of nuts. "At the ... if the coughing was related to his illness or choking," ... cold. A cashew had become lodged in his windpipe and ...
(Date:8/1/2014)... For years, proponents have praised breast-feeding as ... conducted by the Ohio State University, suggests that ... terms of their health and development, raising questions among ... their baby. So does this new research change the ... , chair of Pediatrics at Abington Memorial Hospital, not ...
(Date:8/1/2014)... 2014 (BRONX, NY) Scientists at Albert ... found that bacteria that aid in digestion help keep ... the journal Immunity , could yield new therapies ... of other disorders. , The research involved the intestinal ... of these microorganisms in promoting or preventing disease is ...
(Date:8/1/2014)... In today’s age, traditional learning methods are futile in ... methods need to be revamped, so that the necessary ... this age of the internet, online learning resources act ... management systems help in the planning, implementation, and assessment ... are proving to be very useful and this trend ...
Breaking Medicine News(10 mins):Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 4
... 10 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today ... results on Monday, April 28, 2008 at approximately,4:00 p.m. ... a,conference call at 4:30 p.m. ET. Henry L. Nordhoff, ... president, finance, and,chief financial officer, will host the call., ...
... provide more on ,how to, than ,how to prevent, ... study says that people surfing the Web for information about ... act rather than offering help and support. , Researchers from ... search terms, one at a time, into each of the ...
... Collaboration Platform is Gaining ... Significant Usage in the Healthcare Vertical, ... market,leader in delivering effective and easy-to-use Web 2.0 ... corporations and,membership organizations, is pleased to announce a ...
... Ensure Union Democracy, OAKLAND, Calif., April ... restore democracy to the nation,s largest union ... which will be,considered at the union,s upcoming ... proposed by members of United Healthcare,Workers-West, SEIU,s ...
... IRIDEX,Corporation (Nasdaq: IRIX ) today reported final financial results ... Revenue for the fourth quarter of 2007 was $14.1 ... fourth quarter of 2006. The,Company,s net loss was $15.8 million ... compared with a loss of $3.8 million or $0.48 per,diluted ...
... dramatically reduced with this method, researchers find , , ... fresh fruits and vegetables can reduce the risk ... all disease-causing bacteria, new research shows. , The ... reviewed by the U.S. Food and Drug Administration, ...
Cached Medicine News:Health News:Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call 2Health News:Suicide Data on Web Mostly Not Preventive 2Health News:Healthcare Sector Benefits from Online Community 2Health News:UHW Unveils Proposals for SEIU Convention 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:Irradiation Almost Erases Risk of Food Poisoning 2Health News:Irradiation Almost Erases Risk of Food Poisoning 3Health News:Irradiation Almost Erases Risk of Food Poisoning 4
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Medicine Products: